Gilead's Truvada May Cut HIV Infection Risk, FDA Says

Law360, New York (May 8, 2012, 7:56 PM EDT) -- Gilead Sciences Inc.'s Truvada, an antiretroviral drug widely used in HIV treatment, is effective at preventing HIV infection in at-risk individuals, according to a U.S. Food and Drug Administration report released Tuesday.

In two separate trials, Truvada's combination of tenofovir and emtricitabine taken as a pre-exposure prophylaxis greatly decreased rates of infection in individuals with HIV-infected sexual partners, according to the report.

The FDA's Antiviral Drugs Advisory Committee on Friday will consider Gilead's request to sell Truvada as a preventive treatment, which has been granted priority...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.